Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule co...Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia were searched from PubMed,the Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,VIP,Wanfang and China Biomedical Literature Databases from establishment of the database to February 2021.Meta-analysis was performed using RevMan5.4 software after two researchers independently screened the literatures,extracted the data and evaluated the bias risks in the included studies according to the Cochrane Collaboration System Evaluator Manual.Results:6 randomized controlled trials involving 1060 patients were included.Meta-analysis results showed that the treatment group was better than the control group in total effective rate(Relative Risk=1.19,95%Confidence Interval(1.10,1.28),P<0.00001),International Prostate Symptom Score(Mean Difference=-2.99,95%confidence interval(-4.00,-1.99),P<0.00001),prostate volume(Mean Difference=-3.77,95%Confidence Interval(-4.67,-2.86),P<0.00001),postvoid residual urine volume(Mean Difference=-5.96,95%Confidence Interval(-8.15,-3.77),P<0.00001)and maximum urine flow rate(Mean Difference=3.45,95%Confidence Interval(2.53,4.37),P<0.00001).While there was no significant difference in the adverse effects rate(Relative Risk=0.71,95%Confidence Interval(0.33,1.56),P=0.40)between the treatment group and the control group.Conclusion:Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia showed good efficacy and high safety.However,more high-quality and large-sample studies are needed to confirm the above conclusions.展开更多
Objective：To investigate the effect of Longbishu Capsule（癃闭舒胶囊,LBS）,doxazosin,and combination therapy on benign prostatic hyperplasia（BPH）.Methods：A randomized,double-blind,multi-center parallel trial was c...Objective：To investigate the effect of Longbishu Capsule（癃闭舒胶囊,LBS）,doxazosin,and combination therapy on benign prostatic hyperplasia（BPH）.Methods：A randomized,double-blind,multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing（108 cases）,Heilongjiang（90 cases）,Sichuan（90 cases）,Shanghai（72 cases）,China.They were randomly assigned with central randomization method to group A（LBS placebo plus doxazosin）,group B（LBS plus doxazosin）or group C（LBS plus doxazosin placebo）,120 cases for each group.The international prostate symptom score,maximum urinary flow rate,postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.Results：At baseline,there was no significant difference in the measured variables among the three groups.After 12-month treatment,the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline（P〈0.01）.Although postvoid residual urine volume was not significantly different from the baseline in group A（P〉0.05）,it significantly decreased in group B and C（P〈0.05）.The incidence of adverse events were similar among the three groups.Conclusions：The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH.The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.展开更多
文摘Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia were searched from PubMed,the Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,VIP,Wanfang and China Biomedical Literature Databases from establishment of the database to February 2021.Meta-analysis was performed using RevMan5.4 software after two researchers independently screened the literatures,extracted the data and evaluated the bias risks in the included studies according to the Cochrane Collaboration System Evaluator Manual.Results:6 randomized controlled trials involving 1060 patients were included.Meta-analysis results showed that the treatment group was better than the control group in total effective rate(Relative Risk=1.19,95%Confidence Interval(1.10,1.28),P<0.00001),International Prostate Symptom Score(Mean Difference=-2.99,95%confidence interval(-4.00,-1.99),P<0.00001),prostate volume(Mean Difference=-3.77,95%Confidence Interval(-4.67,-2.86),P<0.00001),postvoid residual urine volume(Mean Difference=-5.96,95%Confidence Interval(-8.15,-3.77),P<0.00001)and maximum urine flow rate(Mean Difference=3.45,95%Confidence Interval(2.53,4.37),P<0.00001).While there was no significant difference in the adverse effects rate(Relative Risk=0.71,95%Confidence Interval(0.33,1.56),P=0.40)between the treatment group and the control group.Conclusion:Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia showed good efficacy and high safety.However,more high-quality and large-sample studies are needed to confirm the above conclusions.
基金Supported by the Project of Science Research for the 11th FiveYear Plan(No.2007BAI20B044)
文摘Objective：To investigate the effect of Longbishu Capsule（癃闭舒胶囊,LBS）,doxazosin,and combination therapy on benign prostatic hyperplasia（BPH）.Methods：A randomized,double-blind,multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing（108 cases）,Heilongjiang（90 cases）,Sichuan（90 cases）,Shanghai（72 cases）,China.They were randomly assigned with central randomization method to group A（LBS placebo plus doxazosin）,group B（LBS plus doxazosin）or group C（LBS plus doxazosin placebo）,120 cases for each group.The international prostate symptom score,maximum urinary flow rate,postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.Results：At baseline,there was no significant difference in the measured variables among the three groups.After 12-month treatment,the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline（P〈0.01）.Although postvoid residual urine volume was not significantly different from the baseline in group A（P〉0.05）,it significantly decreased in group B and C（P〈0.05）.The incidence of adverse events were similar among the three groups.Conclusions：The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH.The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.
